CLINICAL TRIALS PROFILE FOR NEOSPORIN

All Clinical Trials for NEOSPORIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	Joseph Eye Hospital	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	Kolokotrones Family Foundation	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	L.V. Prasad Eye Institute	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	Research to Prevent Blindness	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	Thrasher Research Fund	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
NCT00386958 ↗	A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers	Completed	University of California, Los Angeles	Phase 2	2002-11-01	Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.

Clinical Trial Conditions for NEOSPORIN

Condition Name

Condition Name for NEOSPORIN
Intervention	Trials
Bacterial Keratitis	1
Childhood Blindness	1
Corneal Ulcer	1
COVID-19	1

Condition MeSH

Condition MeSH for NEOSPORIN
Intervention	Trials
Corneal Ulcer	1
Blindness	1
COVID-19	1
Wounds and Injuries	1

Clinical Trial Locations for NEOSPORIN

Trials by Country

Trials by Country for NEOSPORIN
Location	Trials
United States	3
Thailand	1

Trials by US State

Trials by US State for NEOSPORIN
Location	Trials
Connecticut	1
Florida	1
California	1

Clinical Trial Progress for NEOSPORIN

Clinical Trial Phase

Clinical Trial Phase for NEOSPORIN
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for NEOSPORIN
Clinical Trial Phase	Trials
Completed	2
Not yet recruiting	1
Unknown status	1

Clinical Trial Sponsors for NEOSPORIN

Sponsor Name

Sponsor Name for NEOSPORIN
Sponsor	Trials
Chulalongkorn University	1
Jacksonville Center For Clinical Research	1
Joseph Eye Hospital	1

Sponsor Type

Sponsor Type for NEOSPORIN
Sponsor	Trials
Other	15
Industry	1

Last updated: April 25, 2026

NEOSPORIN (Topical Combination Products): Clinical Trial Update, Market Analysis, and Projection

What is “NEOSPORIN” as a drug product?

“NEOSPORIN” is a brand label for topical antimicrobial combination products marketed in the U.S. and internationally. In the U.S., the brand is commonly associated with combination topical antibiotic ointments/creams that include one or more of the following actives: bacitracin, neomycin, and polymyxin B (formulation varies by product and country). These are not a single, new molecular entity and do not map to one modern Phase 1-3 development program the way biologics and novel small molecules do.

Because the brand encompasses multiple formulations, “clinical trials” for NEOSPORIN primarily consist of:

• Older or limited-purpose studies tied to wound care and topical infection prevention/management, and
• Regulatory/labeling activities and/or bioequivalence or formulation comparability exercises rather than ongoing late-stage pivotal trials.

What is the current clinical-trials position for NEOSPORIN?

No current, ongoing Phase 2 or Phase 3 pivotal development trials for NEOSPORIN as a modern, brand-led pipeline asset are identifiable from the public record in a way that supports a clean, trial-count and timeline-based projection for the brand as a single “drug.”

What is visible from the regulatory and brand reality is that NEOSPORIN’s value proposition is commercial and formulation-based (topical antibiotic coverage for minor wound care), not driven by a late-stage R&D cycle with new efficacy/safety endpoints.

Practical implication for investors and R&D: treat NEOSPORIN as a mature, line-extension and formulation-portfolio brand, not as a monolithic “clinical trial program” for projection.

---

What does the NEOSPORIN market look like today?

Where does NEOSPORIN compete?

NEOSPORIN competes in topical first-aid and minor wound care across channels that stock:

• OTC topical antibiotic products,
• Antiseptic and wound-care agents,
• Dressing products and related over-the-counter wound management.

Key competitive dynamics:

• Brand switching driven by price, availability, and consumer familiarity,
• Safety and sensitivity perception, especially for neomycin-containing products (contact sensitization risk drives label and patient-education positioning),
• Formulation differences (ointment vs cream; active compositions; packaging; pediatric labeling),
• Retail execution (pharmacy shelf space and e-commerce visibility).

Market definition and forecast approach

A defensible projection requires a consistent market bucket. For NEOSPORIN, the appropriate bucket is OTC topical antibiotic / minor wound care rather than prescription dermatology or systemic infection markets.

Because NEOSPORIN is older and formulation-based, the most decision-relevant drivers for forecast are:

• U.S. OTC minor wound care demand growth (population and household usage),
• Share vs substitutes (antiseptics, barrier preparations, dressing ecosystems),
• Regulatory and safety labeling for contact sensitization risk,
• Channel mix (pharmacy vs mass vs e-commerce),
• Manufacturing continuity and supply (OTC antibiotics are exposed to raw-material and packaging constraints).

---

Market projection: how should NEOSPORIN revenue be modeled?

What drives upside and downside?

Upside drivers

• Continued OTC demand for minor wound care products.
• Brand reinforcement and seasonal demand (injury-driven periods).
• Portfolio breadth via ointment/cream variants (where offered).

Downside drivers

• Consumer preference shift toward non-neomycin options and antiseptic/bandage-based strategies.
• Higher perceived risk of contact dermatitis sensitivity with neomycin-containing products.
• Competitive pricing pressure in OTC first-aid categories.

Base-case projection framework (actionable structure)

Use a share-and-growth model rather than a pipeline model:

1. Market growth: apply category CAGR for OTC minor wound care (unit volume and price mix).
2. Brand share: track NEOSPORIN’s relative share across major channels.
3. Price realization: incorporate OTC price inflation and competitive discounting.
4. Formula mix: shift between ointment and cream SKUs can change average selling price.
5. Risk penalty: apply a structural share headwind if neomycin sensitivity reduces eligible usage.

---

Key business-relevant implications

Does NEOSPORIN have patent-driven pipeline economics?

NEOSPORIN is a mature brand whose economics primarily depend on:

• Ongoing OTC labeling and manufacturing,
• Brand equity and distribution,
• Ongoing availability through supply chains.

It is not characterized by a single, new Phase 2-3 asset that would justify classic “launch timeline” projections based on clinical endpoints.

What does this mean for R&D strategy?

For R&D and partnerships, NEOSPORIN-style assets typically move via:

• formulation optimization,
• sensitization-risk reduction (actives selection, excipient changes),
• delivery system changes (vehicle, moisture balance),
• label expansion consistent with safety data and clinical rationale.

---

Key Takeaways

• NEOSPORIN is a mature topical OTC antibiotic brand spanning combination topical actives such as bacitracin, neomycin, and polymyxin B depending on formulation.
• There is no clean, current late-stage (Phase 2-3) clinical trial program that supports a modern pipeline-style projection for the brand as a single drug asset.
• Market projection should be modeled as an OTC category and share exercise (category growth, competitive substitution, price mix, and neomycin-related sensitivity headwinds), not as a trial-driven launch forecast.

---

FAQs

1) Is NEOSPORIN a single drug with one clinical development program?
No. It is a brand umbrella for multiple topical combination formulations, so clinical activity is not best treated as one unified Phase 2-3 pipeline.

2) What endpoints matter most for NEOSPORIN-like topical antibiotics?
Efficacy in minor wound infection prevention/management and safety, with special attention to contact sensitization risk where neomycin is present.

3) What are the biggest competitive threats to NEOSPORIN?
OTC topical substitutes (antiseptics, barrier approaches, dressing-led strategies) and pricing/availability pressure in minor wound care.

4) How should forecasts be structured for NEOSPORIN?
Use market growth plus brand share plus price realization, with a sensitivity/risk-driven structural headwind.

5) What is the highest-value R&D angle for a NEOSPORIN-style portfolio?
Formulation and delivery optimization that maintains antimicrobial coverage while reducing sensitivity or improving tolerability and user experience.

---

References

[1] U.S. Food and Drug Administration (FDA). Drug Safety-related communications and labeling resources for topical antibiotic products (neomycin contact sensitivity context). https://www.fda.gov/
[2] FDA. OTC drug monographs and regulatory frameworks relevant to topical antibiotic products. https://www.fda.gov/
[3] Global regulatory and labeling databases (product labeling and active-ingredient combinations for OTC topical antibiotics branded as NEOSPORIN). https://www.accessdata.fda.gov/
[4] Clinical trial registry search portals for NEOSPORIN-linked topical antibiotic entries (publicly searchable). https://clinicaltrials.gov/